# OnCo record tadpole (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/tadpole/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "tadpole", "NCT02684058" ;
  schema:name "TADPOLE (CDRB436G2201)"@en ;
  schema:description "The first randomised trial to show that a targeted drug pair beats chemotherapy in children with a brain tumour. Children whose low-grade glioma carries a BRAF V600 mutation had far more tumour shrinkage and a much longer time before progression on dabrafenib plus trametinib than on standard carboplatin and vincristine."@en ;
  schema:url <https://onco.cc/trials/tadpole/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02684058>, <https://doi.org/10.1056/NEJMoa2303815> ;
  onco:status "positive" ;
  onco:tag "nci-coverage", "paediatric", "cns" ;
  onco:phase "2" ;
  schema:startDate "2017-12-28" ;
  onco:cancers <https://onco.cc/cancers/paediatric-low-grade-glioma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/terms/race-for-children-act/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bouffet-n-engl-j-med/> .